Business Wire

FABASOFT

Share
Siemens Energy Consolidates its Forerunner Status With Fabasoft Approve Cross-plant Quality Management Software

Siemens Energy is using Fabasoft Approve as the process-driven quality management solution for its Power Transformer segment. The global rollout of Fabasoft Approve is scheduled for upwards of 3,000 users following the successful completion of pilot projects at the two largest transformer plants in Weiz (Austria) and Nuremberg (Germany).

The challenge for Siemens Energy was to implement a cross-plant quality management tool in one network with 14 locations in eight countries and to digitally map its existing processes. Thanks to its wide range of customization options and high degree of usability, Fabasoft Approve made a convincing case in the multi-stage selection process and stood out as the high-performance platform of choice for computer-aided quality (CAQ) processes. The cloud-based solution offers comprehensive complaint management that can even be handled from a smartphone or tablet – for both in-house use and remote use at the customer’s site. Allocating the necessary immediate, corrective, and preventive actions is a workflow-driven process that can be tracked at any time.

You can find further information in the case study “Achieving predictive quality with Fabasoft Approve cross-plant quality management software”

“The overarching goal of our collaboration with Fabasoft is to achieve data-based prediction for product and process-related quality. Our new cross-plant quality management software affords us the transparency to make the right decisions and proactively avoid potential errors in the future. This way, we can be certain that we’re optimizing both our error costs and the level of customer satisfaction,” explains Stefan Klaassen, Head of Power Transformers, Siemens Energy.

“As a cross-plant quality management solution, Fabasoft Approve supplies all of the relevant product and process data. Thanks to its powerful analysis capabilities, any user can conduct analyses on quality issues with just a few mouse clicks. We are thrilled to be able to play a significant role in data-driven forecasting with Fabasoft Approve," adds Andreas Dangl, Business Unit Executive for Cloud Services at Fabasoft.

About Fabasoft Approve

Fabasoft Approve is a cloud-based off-the-shelf product for managing technical data and documents in an industrial setting. The standard solution integrates all project partners on a secure, scalable, and highly customizable platform. Creating and editing documents, as well as review, release, and approval processes are achieved efficiently and traceably with significantly less manual effort.

About Siemens Energy

With some 91,000 employees, Siemens Energy operates globally along the entire energy value chain. Its products include gas turbines, steam turbines, generators, transformers, and compressors. The company’s Power Transformer segment manufactures the largest transformers for substations located throughout the world.

About Fabasoft

Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon

Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release

The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered

TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents

AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release

Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce

ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release

Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye